Company family · HQ DE
Aristo: medicine shortages
As of 2 Nov 2026, 32 Aristo products have a reported shortage across 4 countries, covering 16 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
Open shortages over time
Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Rosuvastatin | 6 | 24 Mar 2023 | Increased demand | 12/16 | |
| Melperone | 5 | 24 Mar 2023 | Manufacturing problem | 1/16 | |
| Atorvastatin | 3 | 28 Mar 2025 | Increased demand | 11/16 | |
| Nitrendipine | 3 | 2 Jun 2025 | Other | 3/16 | |
| Ramipril and Amlodipine | 3 | 28 May 2026 | Not stated | 3/16 | |
| Acetylsalicylic Acid | 1 | 1 Dec 2025 | Not stated | 7/16 | |
| Desmopressin | 1 | 1 Oct 2026 | Commercial decision or withdrawal | 8/16 | |
| Dronedarone | 1 | 2 Jul 2026 | Increased demand | 3/16 | |
| Dutasteride | 1 | 30 Jun 2023 | Manufacturing problem | 4/16 | |
| Fentanyl | 1 | 20 Oct 2026 | Increased demand | 9/16 | |
| Finasteride | 1 | 1 Dec 2026 | Manufacturing problem | 8/16 | |
| Levonorgestrel | 1 | 20 May 2026 | Not stated | 1/16 | |
| Modafinil | 1 | 6 Jul 2026 | Not stated | 2/16 | |
| Tadalafil | 1 | 16 Nov 2026 | Manufacturing problem | 10/16 | |
| Tolterodine | 1 | 14 Nov 2025 | Increased demand | 8/16 | |
| Ulipristal | 1 | 21 Jul 2026 | Manufacturing problem | 2/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.